research use only

Smurf1-IN-A01 E3 Ligase inhibitor

Name: Smurf1-IN-A01
Brand: Selleck Chemicals
SKU: S0345
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S0345

Smurf1-IN-A01 can inhibit Smurf1-mediated Smad1/5 degradation and accelerate BMP-2 signal responsiveness with a Kd of 3.664 nM.

Chemical Structure

Molecular Weight: 512.93

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.95%

99.95

Related Targets	DUB Proteasome E1 Activating p97 SUMO E2 conjugating
Related Products	Skp2 inhibitor C1 (SKPin C1) PRT4165 Avadomide (CC-122) Apcin SZL P1-41 Mezigdomide (CC-92480) Homo-PROTAC cereblon degrader 1

Chemical Information, Storage & Stability

Molecular Weight	512.93	Formula	C₂₂H₂₀ClF₃N₄O₃S	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1007647-73-5	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	A01, SMURF1 inhibitor A01			Smiles	CC1=CC=NN1C2=CC=C(C=C2)C(=O)N3CCN(CC3)S(=O)(=O)C4=CC(=C(C=C4)Cl)C(F)(F)F

Solubility

In vitro
Batch:

DMSO : 100 mg/mL ( (194.95 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.85mg/ml (1.66mM)	Taking the 1 mL working solution as an example, add 50 μL of 17 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.1mg/ml (0.19mM)	Taking the 1 mL working solution as an example, add 50 μL of 2 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	Smurf1 ^[1] 3.664 nM(Kd)
References	https://pubmed.ncbi.nlm.nih.gov/24828823/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06048536	Completed	Contraception	Viatris Inc.	December 22 2023	Phase 2
NCT06193538	Recruiting	Advanced Glioblastoma Patients	First Affiliated Hospital of Wannan Medical College	September 14 2023	Phase 1
NCT05139121	Active not recruiting	Contraception	Mylan Technologies Inc.\|Mylan Inc.\|Viatris Inc.	October 26 2021	Phase 3
NCT04012242	Unknown status	Nonalcoholic Steatohepatitis\|Ultrasound\|Elastography	Tokyo Medical University	June 15 2019	--
NCT01357993	Completed	Attention-Deficit / Hyperactivity Disorder	Janssen Pharmaceutical K.K.	May 2011	Phase 3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):